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Abstracts / Biol Blood Marrow Transplant 19 (2013) S129eS149 S133Achievement of a complete remission (CR) is considered an
important goal of therapy in multiple myeloma (MM). High
dose chemotherapy with autologous stem cell trans-
plantation (ASCT) was the ﬁrst treatment to reliably produce
CR in MM. Several approaches have been tried to further
increase the CR rate including polychemotherapy prepara-
tive regimens, tandem ASCT, consolidation and/or mainte-
nance therapy. Since there is a dose response effect for
melphalan, we evaluated an alternative single ASCT strategy
using higher dose melphalan at 280 mg/m2 (MEL 280).
Methods: We completed a multicenter, phase II trial of MEL
280 in patients withMMundergoing ASCTafter a median of 1
prior regimen. Twodoses of amifostine (AF) 740mg/m2 IVover
5-15 minutes were administered 24 hour and 15 min before
MEL 280 to ameliorate mucosal toxicity. Between 5/1999 and
10/2003, 58MMpatients (pts) received this highdose regimen
after dexamethasone-based induction regimens. Lenalido-
mide or bortezomib were not used in induction.
Themedian agewas 50 yrs (35-66), 33weremale, median
initial beta 2-microglobulin level was 3.0 mg/L (0.8-22.4).
The subtypes included IgG (n¼ 32), IgA (n ¼15), light chain
(n ¼ 8)and non-secretory (n¼ 3); 67% had Durie Salmon
stage III disease; 90% of pts were chemosensitive to dexa-
methasone-based induction therapy. Median time from
diagnosis to ASCT was 7.5 months.
Toxicity: Bearman critieria were utilized for grading
regimen-related toxicity (RRT): grade 1 mucositis was seen
in 41%, grade 2 in 14% and grade 3 in 1.7%. Other grade 3
toxicities included: lung (1.7%) and renal (1.7%); 1 pt died
from melphalan-induced interstitial pneumonitis; 7% expe-
rienced atrial ﬁbrillation or ﬂutter. Of the 57 evaluable pts, CR
was achieved in 28 (49%), VGPR in 6 (11%), PR in 17 (30%), SD
in 4 (7%) unknown in 1 (1.5%) and progression in 1 (1.5%).
At a median follow-up of 7 yrs, 76% of pts have progressed
and 57% have died. The cause of deathwasMM in 88% (29/33)
and non-relapse causes in 4 (1 lung cancer,1 coronary disease,
1 sepsis and 1 complications of subsequent allogeneic
transplant). The median overall survival (OS) is 67 months
while the median progression-free survival (PFS) is 22
months. PFS and OS at 7 years was 10% and 39% respectively.
Conclusions: MEL 280 + AF is well-tolerated with low
transplant related mortality. Excellent VGPR+CR rates of 60%
were achieved in the pre-novel agent era. However, the high
CR + VGPR rate after ASCT did not translate into an
improvement in PFS/OS from single or tandem ASCT trials in
that era (Barlogie et al. J Clin Oncol. 2010; 28: 1209-14). In
contrast to recent studies showing CR correlates with
improved long term outcomes, MEL 280 dose escalation
increased response depth, however, sustainability of
response is not impacted.43
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Background: High-dose therapy and autologous stem-cell
transplantation (HDT-ASCT) can offer potential long-term
remission or cure in patients with high risk non-Hodgkin's
lymphoma (NHL). Limited experience is available on the
safety and efﬁcacy of HDT-ASCT in elderly patients.
Methods: This is a single-center, retrospective study exam-
ining outcomes of HDT-ASCT for NHL in 145 patients 60 years
and older between January 2001 and December 2010. Clin-
ical data and comorbidities were correlated with outcomes.
Overall survival (OS) and progression-free survival (PFS)
were analyzed according to age at transplant, histology,
hematopoietic cell transplantation comorbidity index (HCT-
CI) and ﬁrst remission versus subsequent remission at the
time of HDT-ASCT.
Results: The median age was 65 (range 60-74). Fifty-nine,
67 and 20 patients were ages 60 - <65, 65 - <70 and >70,
respectively. Patients underwent HDT-ASCT for diffuse large
B-cell lymphoma (DLBCL, n¼57, 39%), mantle cell
lymphoma (MCL, n¼53, 37%) and other NHL subtypes
(n¼35, 24%). HDT-ASCT in ﬁrst remission was performed in
68 patients (47%), mostly with MCL (70%). BEAM and RR-
BEAM were the most common conditioning regimens
(85%). 34 (23%), 35 (24%) and 77 (53%) patients had a low
(0), intermediate (1-2) and high (>3) HCT-CI score at
transplant. Overall, with a median follow-up of 3.2 years
(range 0.2-8.1) for survivors, PFS and OS at 2 years were
71% and 76%, respectively. Age and HCT-CI score did not
affect OS or PFS. Patients with MCL had better outcomes
compared to other NHL histologies with 2 years OS of 90%
versus 65% and PFS of 85% versus 58% respectively. The one
year incidence of progression was 4% in MCL, 28% in DLBCL
and 34% for other NHL histologies. A total of 54 patients
(37%) progressed [24 (44%) DLBCL, 14 (26%) MCL and 16
(30%) others]. Median time to treatment failure was 11.6
months (range 1.3-88). Three (2%) patients died from
transplant complications. High-risk status by HCT-CI was
not associated with TRM. Six patients (4%) developed
secondary myelodysplastic syndrome (MDS) at a median of
40 months (range 5-83).
Conclusion: In this large cohort of elderly patients with NHL
who underwent HDT-ASCT, we demonstrate that this inter-
vention is feasible, tolerable, and effective, and results in
similar disease control and survival as in younger historical
controls. Our data suggest that age alone is not predictive of
post transplant outcomes and therefore should not be used
to preclude HDT-ASCT in elderly.
